These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 25397561)

  • 21. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Darunavir-based dual therapy in HIV experienced patients.
    Sterrantino G; Zaccarelli M; Di Biagio A; Rosi A; Bruzzone B; Cicconi P; Carli T; Biondi ML; Antinori A; Bartolozzi D; Penco G
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19782. PubMed ID: 25397526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients.
    Podzamczer D; Rojas JF; Neves I; Ferrer E; Llibre JM; Leal M; Gorgolas M; Jose CM; Gatell JM; Abreu RC; Curto J; Domingo P; Pilar BM; Rozas N
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19773. PubMed ID: 25397517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients.
    Baldin G; Ciccullo A; Rusconi S; Capetti A; Sterrantino G; Colafigli M; d'Ettorre G; Giacometti A; Cossu MV; Borghetti A; Gennari W; Mussini C; Borghi V; Di Giambenedetto S
    Int J Antimicrob Agents; 2019 Dec; 54(6):728-734. PubMed ID: 31521809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO.
    Molina JM; Clotet B; van Lunzen J; Lazzarin A; Cavassini M; Henry K; Kulagin V; Givens N; Brennan C; de Oliveira CF
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19490. PubMed ID: 25393999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort.
    Rokx C; Fibriani A; van de Vijver D; Verbon A; Schutten M; Gras L; Rijnders BJ
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19491. PubMed ID: 25394000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.
    Arribas JR; Clumeck N; Nelson M; Hill A; van Delft Y; Moecklinghoff C
    HIV Med; 2012 Aug; 13(7):398-405. PubMed ID: 22413874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
    Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
    HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study.
    Neukam K; Espinosa N; Merino D; Rivero-Juárez A; Carrero A; Ríos MJ; Ruiz-Morales J; Gómez-Berrocal A; Téllez F; Díaz-Menéndez M; Collado A; Pérez-Camacho I; Delgado-Fernández M; Vera-Méndez F; Pineda JA
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19631. PubMed ID: 25394135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monotherapy with darunavir/ritonavir is effective and safe in clinical practice.
    Pasquau J; López-Cortés L; Mayorga MI; Viciana P; Del Mar Arenas M; Ríos MJ; Hernández-Quero J; Castaño M; Merino MD; Márquez M; Vergara A; Terrón A; Téllez F; Hidalgo-Tenorio C
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19813. PubMed ID: 25397557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
    Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
    J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function.
    Postorino MC; Quiros-Roldan E; Maggiolo F; Di Giambenedetto S; Ladisa N; Lapadula G; Lorenzotti S; Sighinolfi L; Castelnuovo F; Di Pietro M; Gotti D; Mazzini N; Torti C;
    Open AIDS J; 2016; 10():136-43. PubMed ID: 27563366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients.
    Bernardino JI; Zamora FX; Valencia E; Moreno V; Vergas J; Tellez MJ; Estrada V; Gonzalez-Garcia J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19787. PubMed ID: 25397531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
    Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
    Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
    Pellegrin I; Wittkop L; Joubert LM; Neau D; Bollens D; Bonarek M; Girard PM; Fleury H; Winters B; Saux MC; Pellegrin JL; Thiébaut R; Breilh D;
    Antivir Ther; 2008; 13(2):271-9. PubMed ID: 18505178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
    J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients.
    Lathouwers E; De La Rosa G; Van de Casteele T; Baeten B; Tomaka F; De Meyer S; Picchio G
    Antivir Ther; 2013; 18(3):289-300. PubMed ID: 23558157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI.
    Di Yacovo S; Molto J; Ferrer E; Curran A; Else LJ; Clotet B; Tiraboschi J; Niubo J; Vila A; Podzamczer D
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19821. PubMed ID: 25397565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.